Einloggen

Thematische Bibliographien / Antibodies / Zeitschriftenartikel

Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Antibodies.

Zeitschriftenartikel zum Thema „Antibodies“

Autor: Grafiati

Veröffentlicht am 4. Juni 2021

Zuletzt aktualisiert am 25. Juli 2025

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Antibodies" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

Deora, Kanika, and Ruchee Khanna. "Clinical Profile of the Patients with Antiphospholipid Antibodies: Lupus Anticoagulant and Anticardiolipin Antibodies." Indian Journal of Forensic Medicine and Pathology 12, no. 3 (2019): 195–99. http://dx.doi.org/10.21088/ijfmp.0974.3383.12319.6.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Chiswell, David J., and John McCaffery. "Phage antibodies: will new ‘coliclonal’ antibodies replace monoclonal antibodies?" Trends in Biotechnology 10 (1992): 80–84. http://dx.doi.org/10.1016/0167-7799(92)90178-x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Pooja, Tiwari Patel Pratixa Mishra Satyam Yadav Rubi. "An Extensive Review Study Of Solely Cloned Identical Antibodies - Monoclonal Antibodies." International Journal in Pharmaceutical Sciences 1, no. 12 (2023): 21–34. https://doi.org/10.5281/zenodo.10251264.

Der volle Inhalt der Quelle

Annotation:

Since they were developed, monoclonal antibodies have been studied for potential therapeutic use. The forefront of modern medicine's move towards a new era of individualized therapy is the use of monoclonal antibodies to treat a range of ailments. Monoclonal antibodies can be employed for therapeutic, imaging, and diagnostic applications and have a very high clinical significance. Monoclonal antibodies have a variety of intriguing potential clinical uses. Because the monoclonal antibodies used were either produced in mice or rats, there is currently a risk of disease transfer from mice to peop

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Linhardt, Robert J., C. W. Abell, R. M. Denney, et al. "Monoclonal antibodies and immobilized antibodies." Applied Biochemistry and Biotechnology 15, no. 1 (1987): 53–80. http://dx.doi.org/10.1007/bf02798506.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Favoreel, Herman W., Geert Van Minnebruggen, Gerlinde R. Van de Walle, Jolanta Ficinska, and Hans J. Nauwynck. "Herpesvirus interference with virus-specific antibodies: Bridging antibodies, internalizing antibodies, and hiding from antibodies." Veterinary Microbiology 113, no. 3-4 (2006): 257–63. http://dx.doi.org/10.1016/j.vetmic.2005.11.003.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Clark, A. "Antibodies." Journal of Clinical Pathology 42, no. 5 (1989): 559. http://dx.doi.org/10.1136/jcp.42.5.559-c.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Bradbury, Andrew, Nileena Velappan, Vittorio Verzillo, et al. "Antibodies in proteomics I: generating antibodies." Trends in Biotechnology 21, no. 6 (2003): 275–81. http://dx.doi.org/10.1016/s0167-7799(03)00112-4.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Kounis, Nicholas G., George D. Soufras, and George N. Kounis. "Antibodies against antibodies inducing Kounis syndrome." International Journal of Cardiology 168, no. 5 (2013): 4804–5. http://dx.doi.org/10.1016/j.ijcard.2013.07.037.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Trier, Nicole, Paul Hansen, and Gunnar Houen. "Peptides, Antibodies, Peptide Antibodies and More." International Journal of Molecular Sciences 20, no. 24 (2019): 6289. http://dx.doi.org/10.3390/ijms20246289.

Der volle Inhalt der Quelle

Annotation:

The applications of peptides and antibodies to multiple targets have emerged as powerful tools in research, diagnostics, vaccine development, and therapeutics. Antibodies are unique since they, in theory, can be directed to any desired target, which illustrates their versatile nature and broad spectrum of use as illustrated by numerous applications of peptide antibodies. In recent years, due to the inherent limitations such as size and physical properties of antibodies, it has been attempted to generate new molecular compounds with equally high specificity and affinity, albeit with relatively

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Matraszek, Veronika Viktoria, Hynek Heřman, and Ilona Hromadníková. "The relevance of antiphospholipid antibodies in obstetrics." Česká gynekologie 89, no. 3 (2024): 237–44. http://dx.doi.org/10.48095/cccg2024237.

Der volle Inhalt der Quelle

Annotation:

Summary: Aim and methodology: To provide a comprehensive review on new findings and current recommendations regarding antiphospholipid antibodies with particular emphasis on clinical impact on gestation. Conclusion: Antiphospholipid antibodies are an important risk factor for the development of a series of pregnancy-related complications. Early diagnosis and appropriate therapy can reduce the incidence of pregnancy loss and pregnancy-related complications. Key words: antiphospholipid antibodies – antiphospholipid syndrome – lupus anticoagulant – anticardiolipin antibodies – anti-ß2-glycoprotei

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

Qian, J., Y. Xing, D. Yufang, et al. "OP0216 THE CLINICAL AND PATHOLOGICAL ROLES OF AUTOANTIBODIES TARGETING BMP SIGNALING IN SYSTEMIC LUPUS ERYTHEMATOSUS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 141.1–142. http://dx.doi.org/10.1136/annrheumdis-2023-eular.3682.

Der volle Inhalt der Quelle

Annotation:

BackgroundPulmonary arterial hypertension (PAH) is one of the most severe complications and the leading cause of death in patients with systemic lupus erythematosus (SLE). Pathogenic mechanisms leading to SLE-PAH are still not fully understood. In idiopathic PAH, the dysfunction of the bone morphogenetic protein (BMP) pathway was found to be involved in pulmonary artery remodeling [1]. In SLE-PAH, our previous study identified serum autoantibodies targeting BMP receptors (BMPR) as the potential biomarker, including anti-BMPR2, BMPR1A, and Activin Receptor-Like Kinase type 1 (ALK1) antibodies [

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

Khan, Ramsha, Melissa Menard, Chao-Ching Jen, Xi Chen, Peter A. A. Norris, and Alan H. Lazarus. "Inhibition of platelet phagocytosis as an in vitro predictor for therapeutic potential of RBC antibodies in murine ITP." Blood 135, no. 26 (2020): 2420–24. http://dx.doi.org/10.1182/blood.2019003646.

Der volle Inhalt der Quelle

Annotation:

Abstract Polyclonal anti-D is a first-line therapy for immune thrombocytopenia (ITP). Monoclonal antibodies are desirable alternatives, but none have yet proven successful despite their ability to opsonize erythrocytes (or red blood cells, RBCs) and cause anemia. Here, we examined 12 murine erythrocyte–specific antibodies of different specificity and subtypes and found that 8 of these antibodies could induce anemia in antigen-positive mice. Of these 8 antibodies, only 5 ameliorated ITP. All antibodies were examined for their in vitro ability to support macrophage-mediated phagocytosis of eryth

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

Reddy, Raghuram, Joel Mintz, Roei Golan, et al. "Antibody Diversity in Cancer: Translational Implications and Beyond." Vaccines 10, no. 8 (2022): 1165. http://dx.doi.org/10.3390/vaccines10081165.

Der volle Inhalt der Quelle

Annotation:

Patients with cancer tend to develop antibodies to autologous proteins. This phenomenon has been observed across multiple cancer types, including bladder, lung, colon, prostate, and melanoma. These antibodies potentially arise due to induced inflammation or an increase in self-antigens. Studies focusing on antibody diversity are particularly attractive for their diagnostic value considering antibodies are present at an early diseased stage, serum samples are relatively easy to obtain, and the prevalence of antibodies is high even when the target antigen is minimally expressed. Conversely, the

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

Rathod, PG1* Singh VK1 and Parasana DK2. "Immunochemical techniques: An Overview." Science World a monthly e magazine 2, no. 12 (2022): 2024–31. https://doi.org/10.5281/zenodo.7414424.

Der volle Inhalt der Quelle

Annotation:

Immunochemical techniques are based on a reaction of antigen with antibody, or more exactly, on a reaction of an antigenic determinants with the binding site of the antibody. The antibodies used are produced by various ways. Monoclonal antibodies are products of a single clone of plasma cells derived from B-lymphocytes, prepared in the laboratory by hybridoma technology, based on cellular fusion of tumor (myeloma) cells with splenic lymphocytes of immunized mice. Monoclonal antibodies are directed against single epitope; and are all identical copies of immunoglobulin molecule with the same pri

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

Shoenfeld, Yehuda. "The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies." Nature Medicine 10, no. 1 (2004): 17–18. http://dx.doi.org/10.1038/nm0104-17.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

Bobrovnik, S. A., M. O. Demchenko, and S. V. Komisarenko. "Effect of trifluoroethanol on antibodies binding properties." Ukrainian Biochemical Journal 95, no. 1 (2023): 20–30. http://dx.doi.org/10.15407/ubj95.01.020.

Der volle Inhalt der Quelle

Annotation:

The studies on the influence of organic co-solvents on the structure and function of antibodies are of key interest, especially in view of antibodies broad use as recognizing elements in different analytical systems. Here we studied the effect of co-solvent 2,2,2-trifluoroethanol (TFE) on the ability of anti-ovalbumin monoclonal antibodies to interact with its specific antigen. Antibody affinity to antigen and the rate constants of antibody binding to immobilized antigen were analyzed. Changes in antibody reactivity with incubation time which depended on TFE concentration and temperature were

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

Dahl, Mark V., and Alina G. Bridges. "Intravenous immune globulin: Fighting antibodies with antibodies." Journal of the American Academy of Dermatology 45, no. 5 (2001): 775–83. http://dx.doi.org/10.1067/mjd.2001.119085.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

SHITARA, Kenya. "Potelligent Antibodies as Next Generation Therapeutic Antibodies." YAKUGAKU ZASSHI 129, no. 1 (2009): 3–9. http://dx.doi.org/10.1248/yakushi.129.3.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

Methe, H. "Antibodies Stop Secretion of Antibodies in Lupus." Science Translational Medicine 4, no. 141 (2012): 141ec115. http://dx.doi.org/10.1126/scitranslmed.3004529.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

Filatova, Elena A., Grigory B. Krapivinsky, Grigory N. Filatov, Alisa V. Lazareva, and Evgeny E. Fesenko. "Antiidiotypic antibodies against anti-cGMP polyclonal antibodies." Biochimica et Biophysica Acta (BBA) - Biomembranes 1064, no. 2 (1991): 293–96. http://dx.doi.org/10.1016/0005-2736(91)90314-x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

Nikita, Sapkal Ritesh Rathod* Sakshi Lande Pallavi Radal Haridas Khose. "Monoclonal Antibodies: Insight Review." International Journal of Pharmaceutical Sciences 2, no. 12 (2024): 249–64. https://doi.org/10.5281/zenodo.14265260.

Der volle Inhalt der Quelle

Annotation:

Monoclonal antibodies (mAbs) are a significant achievement in biotechnology and medicine. Kohler and Milstein's Nobel Prize-winning research on murine hybridoma technology in 1975 resulted in the development of mAbs, which are designed to function as substitute antibodies that can restore, augment, or mimic the immune system's attack on cancer cells and other infections. In 1986, the FDA approved the first monoclonal antibody, Orthoclone OKT3® (muromonab-CD3), a huge step forward in antibody research and development. Monoclonal antibodies are glycoproteins produced by identical B cell clon

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

Heng, Boon Chin, Wenjin Huang, Xiufang Zhong, Ping Yin, and Guo Qing Tong. "Roles of Antiphospholipid Antibodies, Antithyroid Antibodies and Antisperm Antibodies in Female Reproductive Health." Integrative Medicine International 2, no. 1-2 (2015): 21–31. http://dx.doi.org/10.1159/000381900.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

BYGREN, P., N. RASMUSSEN, B. ISAKSSON, and J. WIESLANDER. "Anti-neutrophil cytoplasm antibodies, anti-GBM antibodies and anti-dsDNA antibodies in glomerulonephritis." European Journal of Clinical Investigation 22, no. 12 (1992): 783–92. http://dx.doi.org/10.1111/j.1365-2362.1992.tb01447.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

Van de Perre, Philippe, Penny L. Moore, Nicolas Nagot, Lucio Gama, and Jean-Pierre Moles. "Broadly neutralizing antibodies, nonneutralizing antibodies and broadly effector antibodies to prevent HIV transmission?" AIDS 39, no. 7 (2025): 918–20. https://doi.org/10.1097/qad.0000000000004115.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

Kapustianenko, L. G. "POLYCLONAL ANTIBODIES AGAINST HUMAN PLASMINOGEN KRINGLE 5." Biotechnologia Acta 10, no. 3 (2017): 41–49. http://dx.doi.org/10.15407/biotech10.03.041.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

Yatsenko, T. A. "POLYCLONAL ANTIBODIES AGAINST HUMAN PLASMINOGEN: PURIFICATION, CHARACTERIZATION AND APPLICATION." Biotechnologia Acta 13, no. 6 (2020): 50–57. http://dx.doi.org/10.15407/biotech13.06.050.

Der volle Inhalt der Quelle

Annotation:

The plasminogen/plasmin system plays a crucial role in fibrinolysis and regulation of cell functions in a wide range of normal and pathological processes. Investigation of plasminogen/plasmin functions requires the availability of well-characterized and effective molecular tools, such as antibodies. In the present work, the isolation and characterization of rabbit polyclonal antibodies against human plasminogen are described and approaches for the identification of plasminogen and its fragments using the purified antibodies are demonstrated. For the antibodies isolation, standard animal immuni

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

Triplett, Douglas A. "Antiphospholipid Antibodies." Archives of Pathology & Laboratory Medicine 126, no. 11 (2002): 1424–29. http://dx.doi.org/10.5858/2002-126-1424-aa.

Der volle Inhalt der Quelle

Annotation:

Abstract Objective.—To review the role of lupus anticoagulants in the pathogenesis of both venous and arterial thromboembolic events, as well as in recurrent spontaneous abortions. The pathophysiology of lupus anticoagulants and associated antiphospholipid antibodies (eg, anticardiolipin antibodies) is also discussed. Data Sources.—Review of the recent medical literature. Data Extraction and Synthesis.—Key articles in the recent medical literature dealing with lupus anticoagulants and their role in pathogenesis of thromboembolic events were reviewed. Plasma proteins that have an affinity for b

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

Brinkmann, Ulrich, and Roland E. Kontermann. "Bispecific antibodies." Science 372, no. 6545 (2021): 916–17. http://dx.doi.org/10.1126/science.abg1209.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

Rieger, Paula Trahan. "Monoclonal Antibodies." American Journal of Nursing 87, no. 4 (1987): 469. http://dx.doi.org/10.2307/3470440.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

Groner, Bernd, Cord Hartmann, and Winfried Wels. "Therapeutic Antibodies." Current Molecular Medicine 4, no. 5 (2004): 539–47. http://dx.doi.org/10.2174/1566524043360483.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

Kosmas, C., H. Kalofonos, and A. A. Epenetos. "Monoclonal Antibodies." Drugs 38, no. 5 (1989): 645–57. http://dx.doi.org/10.2165/00003495-198938050-00001.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

Larrick, James W., and Kirk E. Fry. "Recombinant antibodies." Human Antibodies 2, no. 4 (1991): 172–89. http://dx.doi.org/10.3233/hab-1991-2401.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

Bronson, Richard A. "Sperm Antibodies." Immunology and Allergy Clinics of North America 10, no. 1 (1990): 165–84. http://dx.doi.org/10.1016/s0889-8561(22)00256-9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

Pisetsky, David S. "ANTINUCLEAR ANTIBODIES." Immunology and Allergy Clinics of North America 14, no. 2 (1994): 371–85. http://dx.doi.org/10.1016/s0889-8561(22)00780-9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

Smith, J. Bruce, and F. Susan Cowchock. "ANTIPHOSPHOLIPID ANTIBODIES." Immunology and Allergy Clinics of North America 14, no. 4 (1994): 821–34. http://dx.doi.org/10.1016/s0889-8561(22)00345-9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

Pratt, Donna E. "THYROID ANTIBODIES." Immunology and Allergy Clinics of North America 14, no. 4 (1994): 835–38. http://dx.doi.org/10.1016/s0889-8561(22)00346-0.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

Visan, Ioana. "Enhancing antibodies." Nature Immunology 22, no. 7 (2021): 800. http://dx.doi.org/10.1038/s41590-021-00973-7.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

38

Khamashta, Munther A., and Graham R. V. Hughes. "Antiphospholipid antibodies." Clinical Reviews in Allergy 12, no. 3 (1994): 287–96. http://dx.doi.org/10.1007/bf02802323.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

39

Adair, J., and A. Lawson. "Therapeutic Antibodies." Drug Design Reviews - Online 2, no. 3 (2005): 209–17. http://dx.doi.org/10.2174/1567269053828800.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

40

Pullen, Richard L. "Antinuclear antibodies." Nursing Made Incredibly Easy! 20, no. 6 (2022): 47–48. http://dx.doi.org/10.1097/01.nme.0000884112.83689.31.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

41

Santos-Argumedo, Leopoldo. "Natural Antibodies." Advances in Neuroimmune Biology 3, no. 3,4 (2012): 345–52. http://dx.doi.org/10.3233/nib-012912.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

42

&NA;. "Monoclonal antibodies." Reactions Weekly &NA;, no. 1293 (2010): 36. http://dx.doi.org/10.2165/00128415-201012930-00100.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

43

Hudson, Peter J., and Christelle Souriau. "Engineered antibodies." Nature Medicine 9, no. 1 (2003): 129–34. http://dx.doi.org/10.1038/nm0103-129.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

44

Benkovic, Stephen J. "Catalytic Antibodies." Annual Review of Biochemistry 61, no. 1 (1992): 29–54. http://dx.doi.org/10.1146/annurev.bi.61.070192.000333.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

45

Harris, E. Nigel. "ANTIPHOSPHOLIPID ANTIBODIES." British Journal of Haematology 74, no. 1 (2008): 1–9. http://dx.doi.org/10.1111/j.1365-2141.1988.00491.x-i1.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

46

Harris, E. Nigel. "ANTIPHOSPHOLIPID ANTIBODIES." British Journal of Haematology 74, no. 1 (1990): 1–9. http://dx.doi.org/10.1111/j.1365-2141.1990.tb02530.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

47

Drlicek, M., U. Liszka, W. Grisold, A. Mohn-Staudner, F. Lintner, and K. Jellinger. "Antineuronal antibodies." Neurology 40, no. 11 (1990): 1804. http://dx.doi.org/10.1212/wnl.40.11.1804-b.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

48

Helmerhorst, F. M., M. J. J. Finken, and J. J. Erwich. "Antisperm antibodies." Human Reproduction 14, no. 7 (1999): 1669–71. http://dx.doi.org/10.1093/humrep/14.7.1669.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

49

Worland, PhD, Peter J., Gary S. Gray, PhD, Mark Rolfe, PhD, Karen Gray, PhD, and Jeffrey S. Ross, MD. "Anticancer Antibodies." American Journal of Clinical Pathology 119, no. 4 (2003): 472–85. http://dx.doi.org/10.1309/y6lp-c0lr-726l-9dx9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

50

Ross, Jeffrey S., Karen Gray, Gary S. Gray, Peter J. Worland, and Mark Rolfe. "Anticancer Antibodies." American Journal of Clinical Pathology 119, no. 4 (2003): 472–85. http://dx.doi.org/10.1309/y6lpc0lr726l9dx9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!